Sign inJoin waitlistJoin the waitlist

Jennifer Leddon

Assistant Professor · University of Cincinnati Medical Center Inc.

Credentials: · · · · ·

History

University of Cincinnati Medical Center Inc.
Present
University of Cincinnati College of Medicine
Present

Hematology and Medical Oncology
University of Cincinnati
2019–2022
Internal Medicine
University of Cincinnati Medical Center Inc.
2016–2019
University of Cincinnati College of Medicine
2012–2016
University of Cincinnati
2010–2015
University of Alabama
2008–2012

Research

Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation
Cell · 2008 · 284 citations
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy
Nano Letters · 2006 · 151 citations
Going back to class I: MHC and immunotherapies for childhood cancer
Review · Pediatric Blood & Cancer · 2015 · 59 citations

Timothy Cripe
8 papers
KH
Kellie Haworth
5 papers
Trisha Wise-Draper
5 papers · 1 as a fellow
Keri Streby
3 papers · 3 as a fellow
Alice Tang
2 papers
Alicia Waters
2 papers · 2 as a resident
AS
Ammar Sukari
2 papers
Elizabeth Beierle
2 papers
Gregory Friedman
2 papers
HS
Hira Shaikh
2 papers · 1 as a fellow
James Markert
2 papers
Jason Frischer
2 papers

Clinical trials

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Site PI · Recruiting · Phase 1, Phase 2
TRIANA Biomedicines, Inc.
2026–2034
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Aminex Therapeutics, Inc.
2026–2028
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.
2025–2029
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2025–2029